Cargando…

Immunotherapy: an alternative promising therapeutic approach against cancers

The immune system interacts with cancer cells in multiple intricate ways that can shield the host against hyper-proliferation but can also contribute to malignancy. Understanding the protective roles of the immune system in its interaction with cancer cells can help device new and alternate therapeu...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Sneh Lata, Basu, Srijani, Soni, Vijay, Jaiswal, Rishi K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244230/
https://www.ncbi.nlm.nih.gov/pubmed/35759082
http://dx.doi.org/10.1007/s11033-022-07525-8
_version_ 1784738479570157568
author Gupta, Sneh Lata
Basu, Srijani
Soni, Vijay
Jaiswal, Rishi K.
author_facet Gupta, Sneh Lata
Basu, Srijani
Soni, Vijay
Jaiswal, Rishi K.
author_sort Gupta, Sneh Lata
collection PubMed
description The immune system interacts with cancer cells in multiple intricate ways that can shield the host against hyper-proliferation but can also contribute to malignancy. Understanding the protective roles of the immune system in its interaction with cancer cells can help device new and alternate therapeutic strategies. Many immunotherapeutic methodologies, including adaptive cancer therapy, cancer peptide vaccines, monoclonal antibodies, and immune checkpoint treatment, have transformed the traditional cancer treatment landscape. However, many questions remain unaddressed. The development of personalized combination therapy and neoantigen-based cancer vaccines would be the avant-garde approach to cancer treatment. Desirable chemotherapy should be durable, safe, and target-specific. Managing both tumor (intrinsic factors) and its microenvironment (extrinsic factors) are critical for successful immunotherapy. This review describes current approaches and their advancement related to monoclonal antibody-related clinical trials, new cytokine therapy, a checkpoint inhibitor, adoptive T cell therapy, cancer vaccine, and oncolytic virus. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11033-022-07525-8.
format Online
Article
Text
id pubmed-9244230
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-92442302022-06-30 Immunotherapy: an alternative promising therapeutic approach against cancers Gupta, Sneh Lata Basu, Srijani Soni, Vijay Jaiswal, Rishi K. Mol Biol Rep Review The immune system interacts with cancer cells in multiple intricate ways that can shield the host against hyper-proliferation but can also contribute to malignancy. Understanding the protective roles of the immune system in its interaction with cancer cells can help device new and alternate therapeutic strategies. Many immunotherapeutic methodologies, including adaptive cancer therapy, cancer peptide vaccines, monoclonal antibodies, and immune checkpoint treatment, have transformed the traditional cancer treatment landscape. However, many questions remain unaddressed. The development of personalized combination therapy and neoantigen-based cancer vaccines would be the avant-garde approach to cancer treatment. Desirable chemotherapy should be durable, safe, and target-specific. Managing both tumor (intrinsic factors) and its microenvironment (extrinsic factors) are critical for successful immunotherapy. This review describes current approaches and their advancement related to monoclonal antibody-related clinical trials, new cytokine therapy, a checkpoint inhibitor, adoptive T cell therapy, cancer vaccine, and oncolytic virus. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11033-022-07525-8. Springer Netherlands 2022-06-27 2022 /pmc/articles/PMC9244230/ /pubmed/35759082 http://dx.doi.org/10.1007/s11033-022-07525-8 Text en © This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Review
Gupta, Sneh Lata
Basu, Srijani
Soni, Vijay
Jaiswal, Rishi K.
Immunotherapy: an alternative promising therapeutic approach against cancers
title Immunotherapy: an alternative promising therapeutic approach against cancers
title_full Immunotherapy: an alternative promising therapeutic approach against cancers
title_fullStr Immunotherapy: an alternative promising therapeutic approach against cancers
title_full_unstemmed Immunotherapy: an alternative promising therapeutic approach against cancers
title_short Immunotherapy: an alternative promising therapeutic approach against cancers
title_sort immunotherapy: an alternative promising therapeutic approach against cancers
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244230/
https://www.ncbi.nlm.nih.gov/pubmed/35759082
http://dx.doi.org/10.1007/s11033-022-07525-8
work_keys_str_mv AT guptasnehlata immunotherapyanalternativepromisingtherapeuticapproachagainstcancers
AT basusrijani immunotherapyanalternativepromisingtherapeuticapproachagainstcancers
AT sonivijay immunotherapyanalternativepromisingtherapeuticapproachagainstcancers
AT jaiswalrishik immunotherapyanalternativepromisingtherapeuticapproachagainstcancers